The Lipid-Lowering Agents market in Israel has been experiencing steady growth over the past few years.
Customer preferences: The demand for Lipid-Lowering Agents in Israel is driven by the increasing prevalence of cardiovascular diseases, which are the leading cause of death in the country. As a result, there is a high demand for drugs that can help manage cholesterol levels and reduce the risk of heart disease. Patients in Israel are also increasingly seeking out more effective and convenient treatments for their conditions, which has led to a rise in the use of combination therapies and newer, more innovative drugs.
Trends in the market: One of the key trends in the Lipid-Lowering Agents market in Israel is the increasing use of PCSK9 inhibitors, which are a newer class of drugs that have been shown to be highly effective in lowering cholesterol levels. These drugs are typically used in combination with statins and have been approved for use in patients who have not responded to other treatments. Another trend in the market is the growing use of combination therapies, which involve the use of two or more drugs to manage cholesterol levels. This approach has been shown to be more effective than using a single drug and is becoming increasingly popular among patients in Israel.
Local special circumstances: Israel has a highly advanced healthcare system, which has helped to drive the growth of the Lipid-Lowering Agents market in the country. The government provides universal healthcare coverage to all citizens, which has helped to ensure that patients have access to the latest treatments and therapies. In addition, Israel has a highly educated population that is well-informed about healthcare and is willing to invest in their health.
Underlying macroeconomic factors: The Lipid-Lowering Agents market in Israel is also being driven by broader macroeconomic factors, such as the country's aging population and the increasing prevalence of chronic diseases. As the population ages, the demand for healthcare services is expected to increase, which will drive demand for Lipid-Lowering Agents and other drugs. In addition, Israel has a high rate of obesity, which is a major risk factor for heart disease and other chronic conditions. This is expected to drive demand for Lipid-Lowering Agents in the country in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
